Management of Hepatitis B Patients Requiring Anti-TB Therapy

Pre-Treatment Screening and Monitoring

The American Academy of Dermatology recommends that all patients undergo hepatitis B and C screening prior to starting anti-TB medications, regardless of risk factors 2, 3
Baseline hepatic measurements, including liver enzymes and bilirubin, should be obtained in patients with chronic hepatitis B, as this is a recognized risk factor for drug-induced hepatotoxicity 4, 3
The Centers for Disease Control and Prevention (CDC) recommends ruling out active TB disease through history, physical examination, chest radiography, and bacteriologic studies before beginning treatment 5, 4

The American Academy of Dermatology recommends that HBsAg-positive patients require hepatology consultation before starting immunosuppressants or anti-TB biologics due to high HBV reactivation risk 2
The American Academy of Dermatology also recommends that anti-TB medications can still be initiated in HBsAg-positive patients, but with heightened monitoring and hepatology co-management 2

The American Academy of Dermatology recommends that the preferred regimen for latent TB infection includes 4 months of rifampin monotherapy, which is as effective as 9 months of isoniazid with superior treatment completion and safety 1, 2
The CDC recommends that for patients with HIV or radiographic evidence of prior TB, 9 months of isoniazid is preferred over 6 months 5, 4

The CDC recommends monthly clinical evaluations checking for signs of hepatitis, including questioning about symptoms and brief physical assessment 5, 4
The CDC also recommends that routine laboratory monitoring is indicated for patients with baseline liver abnormalities or those at risk for hepatic disease 4

The American Academy of Dermatology recommends caution with rifampin in patients with hepatitis B/C due to hepatotoxicity risk documented in retrospective studies 1
The American Academy of Dermatology also recommends that rifampin remains part of standard regimens and can be used with appropriate monitoring 1, 2

The American Academy of Dermatology recommends that TB treatment should not be delayed solely due to hepatitis B status in non-cirrhotic patients—the risk of untreated TB outweighs hepatotoxicity concerns with appropriate monitoring 1, 2
The CDC recommends that the rifampin-pyrazinamide combination should not be used for LTBI in patients with any form of liver disease—this combination has unacceptably high rates of severe hepatotoxicity and death 3

The CDC recommends that if hepatotoxicity develops during treatment, all hepatotoxic drugs should be stopped immediately and bridge therapy initiated with streptomycin plus ethambutol 7, 6
The CDC also recommends that once liver function normalizes, drugs should be reintroduced sequentially with daily monitoring 7, 6